Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension

              Author:Montalban, Xavier   Wolinsky, Jerry S.   Arnold, Douglas L.   Weber, Martin S.   Piasecka-Stryczynska, Karolina   Tomic, Davorka   Seitzinger, Andrea   Guehring, Hans   

              Session Name:S16: MS Clinical Trials and Therapeutics  

              Topic:MS and Inflammatory Disease  

              Program Number:S16.008  

              Author Institution:Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain  McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX  NeuroRx Research, and Montreal Neurological Institute, Montreal, QC, Canada  Institute of Neuropathology and the Department of Neurology, University Medical Center, University of Göttingen, Göttingen, Germany  Poznan University of Medical Sciences, Poznan, Poland  Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany , Eysins, Switzerland  the healthcare business of Merck KGaA, Darmstadt, Germany, Darmstadt, Germany